Expansion of Th1-like Vγ9Vδ2T cells by new generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.
Expansion of Th1-like Vγ9Vδ2T cells by new generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.
复制标题
通过新一代 IMiD、来那度胺和泊马度胺与唑来膦酸联合扩增 Th1 样 Vγ9Vδ2T 细胞。
作者：
2. Harada T;Miki H;Cui Q;Oda A;Amachi R;Teramachi J;Bat-Erdene A;Sogabe K;Iwasa M;Fujii S;Nakamura S;Kagawa K;Yoshida S;Endo I;Aihara K;Ozaki S;Matsumoto T;Abe M.
多发性骨髓瘤（MM）仍然无法治愈，即使实施新的治疗方式，导致开发各种形式的免疫疗法的想法。一种这样的方法是应用γδ T细胞。与NK细胞类似，γδ T细胞是对抗感染和肿瘤的一线防御中的重要效应子，并且在宿主防御和肿瘤监视中具有关键作用。1-3在人类中，γδ T细胞通过T细胞受体V基因的使用分为两个主要亚群，即Vδ1 γδT细胞和Vγ 9 V δ2 γδ T（γδ2 T）细胞。γδ2 T细胞
Multiple myeloma (MM) still remains incurable even with the implementation of novel therapeutic modalities, leading to the idea to develop various forms of immunotherapies. One such approach is the application of γδ T cells. Similar to NK cells, γδ T cells are important effectors in the first-line defense against infections and tumors, and have a critical role in host defense and tumor surveillance. 1-3 In human, γδ T cells are divided into two predominant subpopulations by T-cell receptor V gene usage, namely Vδ1 γδT cells and Vγ9Vδ2 γδ T (γδ2 T) cells. γδ2 T cells